TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04056520

Intervention type: DEVICE
Intervention: Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system
Description: The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability.
Study: NCT01338350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Inhalation, suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation, solution
Study: NCT03979456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
Study: NCT04070716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Description: For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D laparoscope
Description: For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
Study: NCT02574650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
Description: Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
Study: NCT01813552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir 150 mg oral tablets (50mg x 3), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir 150 mg oral tablets (50mg x 3), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg delayed-release oral capsules, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg oral tablets, once daily
Study: NCT00534118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Given IV
Study: NCT03031470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours).~Reparixin was provided as 33 mg/ml concentrated solution to be diluted for i.v. infusion, packaged into 250 mL clear glass vials. To give a final concentration of 11 mg/mL, the content of a vial (250 ml) was diluted with 500 ml of 0.9% sterile saline to a total volume of 750 ml. The dosing solution was placed in a 1000 ml sterile empty Infusion Bag. Dosing solutions were to be used within 72 h from preparation, unless more restrictive rules.~Reparixin infusion started approximately 60-90 minutes before the anticipated time of OLT. Infusion interruption was allowed for no more than 60 min.~All patients received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.~Patients and allograft survival were monitored up to 1 year after OLT.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The patients who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.
Study: NCT02298166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic stem cell transplantation
Description: In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC.
Study: NCT01617707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam plus propofol
Description: In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
Study: NCT04282265

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Spinach Extract (RSE)
Description: Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
Study: NCT01421303

Intervention type: DRUG
Intervention: Enbrel
Description: Enbrel
Study: NCT00813605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive dummy agent (to maintain blind)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive dummy agent (to maintain blind)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Inactive dummy agent (to maintain blind)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
Study: NCT03822598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques, TRT
Description: TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching Recovery Techniques, TRT
Description: TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
Study: NCT04518150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bakri balloon
Description: the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri balloon
Description: the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
Study: NCT01617707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
Study: NCT01959607

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS 2.2
Description: Single use of the Tobacco Heating System 2.2 (THS 2.2)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own cigarette (CC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Single use of subject's own cigarette (CC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT Gum
Description: Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT Gum
Description: Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
Study: NCT03510598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting machine will be used to perform the treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kybella 20 MG in 2 ML Injection
Description: Injectable drug called KYBELLA® (deoxycholic acid)
Study: NCT00464438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gatifloxacin
Description: Day 1-6 = 1 drop of study medication three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin
Description: Day 1-6 = 1 drop of study medication three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0.5% eye drops
Description: Day 1-6 = 1 drop of study medication three times a day
Study: NCT04735926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 75mcg
Description: Soft gelatin capsule. Oral administration once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 100mcg
Description: Soft gelatin capsule. Oral administration once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 100mcg
Description: Soft gelatin capsule. Oral administration once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol 125mcg
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule. Oral administration once per week.
Study: NCT04665466

Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.
Study: NCT04518150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Uterine Artery Ligation
Description: The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
Study: NCT03066089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfuro
Study: NCT04286841

Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
Study: NCT00987428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonography with or not sphincterotomy
Description: Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual procedure
Description: The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
Study: NCT04960904

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.

Intervention type: DEVICE
Intervention: Dental implant surgery with implants
Description: Adult patients who have had dental implant surgery.
Study: NCT02901002

Intervention type: OTHER
Intervention: Sensory testing in the two hand
Description: spontaneous sensations while watching a hand

Intervention type: OTHER
Intervention: Sensory testing in the two hand
Description: spontaneous sensations while watching a hand

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Score to anxiety-depression scale

Intervention type: OTHER
Intervention: Neuropsychological evaluation
Description: Score to anxiety-depression scale
Study: NCT00338208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in the Use of Low Vision Devices
Study: NCT03195244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic Physical Therapy
Description: Swim Whisperer's Aquatic Therapy Sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Physical Therapy
Description: Swim Whisperer's Aquatic Therapy Sessions
Study: NCT01980303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
Study: NCT00211393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: 600mg. /day for 6 weeks
Study: NCT04151927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric Hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normobaric Normoxia
Description: Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normobaric Normoxia
Description: Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
Study: NCT01456195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fasiglifam placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets
Study: NCT00134654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin
Description: Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin
Description: Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
Study: NCT02938832

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on what food to choose and eat
Description: Dietary advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice on what food to choose and eat
Description: Dietary advice
Study: NCT00791479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265 and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study: NCT00398060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral life-style counseling
Study: NCT00791479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265 and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265 and Lifestyle Measures
Description: Subcutaneous injection once-weekly for up to 12 weeks
Study: NCT01311570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.
Study: NCT01954602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guide-wire cannulation
Description: Direct guide-wire hovering a few millimeters through the catheter or sphincterotome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sphincterotome assisted guide-wire cannulation
Description: Sphincterotome is inserted initially a few millimeters through the papillary orifice
Study: NCT04462549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Facilitation
Description: RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification.
Study: NCT03977194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 every 4 weeks